Join the Tepezza group to help and get support from people like you.
Tepezza News
ENDO: Teprotumumab Shows Long-Term Efficacy for Thyroid Eye Disease
TUESDAY, June 11, 2024 – Most patients with thyroid eye disease treated with teprotumumab do not require additional treatments nearly two years later, according to a study presented at the annual...
Horizon Therapeutics plc Announces FDA Approval of an Update to the Indication Language for Tepezza (teprotumumab-trbw) to Specify its Use in Thyroid Eye Disease (TED) Patients Regardless of Disease Activity or Duration
DUBLIN--(BUSINESS WIRE)--Apr. 14, 2023-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the Indications and Usage...
FDA Approves Tepezza (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED)
DUBLIN--(BUSINESS WIRE)--Jan. 21, 2020-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the U.S. Food and Drug Administration (FDA) has approved Tepezza (teprotumumab-trbw) for the...
Ask a question
To post your own question to this support group, sign in or create an account.